

## **QIBA PET Myocardial Blood Flow (MBF) Biomarker Committee (BC)**

Monday, October 11, 2021, at 9 am CT

### *Call Summary*

*Additional notes provided by Dr. Moody*

In attendance	RSNA Staff
Jonathan B. Moody, PhD (Co-Chair)	Julie Lisiecki
Michael Boss, PhD	
Nancy Obuchowski, PhD	

**Moderator:** Dr. Moody

### **Discussion**

- For rest MBF models, the two same-day levels of the “test.retest” variable (same-day-one-injection, same-day-two-injections) should be combined since no stress agent is involved
- The set of rubidium models (“tracer” fixed to R82 and “stressor.2” fixed to VAS) has the most complete data across “pet.scanner.2” and seemed the most appropriate to report
  - The squared difference between multi-day and same-day-two-injection wCV estimates were similar for rest and stress MBF, which may provide an estimate of the “physiological” component of variability
  - MFR wCV was not associated with “subject.status”, “test.retest”, or “pet.scanner.2”.
- Indicator matrices for each measurand showing which variables may be appropriate for wCV multivariable models were added to the MetaAnalysis document. Red and green blocks indicate which pairwise chi-squared tests failed or succeeded, respectively.
  - Dr Obuchowski noted that even when the chi-squared test succeeds, empty cells in the contingency tables cause ambiguity and indicate a lack of information for multivariable modeling
  - Multivariable models will instead need to be developed for fixed levels of predictors that have sufficient data
  - Mosaic plots of the data were briefly discussed as a possible guide to selecting appropriate variables

### **Action items for Dr. Obuchowski**

- At rest – table 8 – to combine two “test.retest” same-day categories: one estimate and one confidence interval
- At stress – add secondary variables to current rubidium model with primary variables
- MFR – single pooled estimate and confidence interval
  - Can add secondary variables also
- Review the initial mosaic plots to help decide if they will be useful to guide variable selection, or for presentation to justify our variable selection choices

### **Other details**

- Within-subject coefficient of variation (wCV) estimate may be pooled for MFR
- Myocardial Blood Flow (MBF) at rest – based on the current model with primary variables, try adding the secondary variables to the model
- MBF at stress – based on the current model with primary variables, try adding the secondary variables to the model
- MFR – try model adding the secondary variables

### **Action items:**

- Dr. Moody to follow up with co-chairs re: updates
- Dr. Obuchowski to make updates as discussed on the call

- Dr. deKemp to look for methodology papers to support the cross-sectional claim (based on bias and precision)

**Next Call:** October 25, 2021, at 9 am CT (2<sup>nd</sup> and 4<sup>th</sup> Mondays) at 9 am CT

---

Parties interested in joining the [QIBA LinkedIn](#) page for QIBA updates should visit: <https://www.linkedin.com/company/rsna-qiba>

### **Process Committee**

- Profile Editors are encouraged to join the QIBA Process Committee to learn about QIBA writing tips and processes and network with other Profile Editors to exchange best practices
- **QIBA Process Committee Leaders:** [Kevin O'Donnell, MASc](#) (Chair) | [Michael Boss, PhD](#) (Co-Chair)
- **Wiki Resources:** [Dashboard](#) | [Profiles](#) | [QIBA Profile template](#) | [How to Write a QIBA Profile](#) | [Claim Guidance](#)
- **Inventory of QIBA tools:** [QIBA LinkedIn page](#) (please join / follow) | [QIBA News](#) | [QIBA Community](#)
- **Other:** [QIBA Webpage](#) | [QIBA Wiki](#) | [QIBA Biomarker Committees](#) | [QIBA Organization Chart](#) | [Dropbox](#)
- **EndNote:** To obtain access to the RSNA EndNote citations, please email: [sstanfa@rsna.org](mailto:sstanfa@rsna.org).